The FDA Is About to Weigh in on the Great Peptide Debate

The FDA's upcoming decision on peptides could reshape the landscape of the booming wellness market, especially as it concerns peptides that are currently sold directly to consumers. This vote will determine if these products, which have surged in popularity, will now be available through licensed pharmacies instead. The implications are significant, as this could lead to better regulation and oversight, potentially enhancing consumer safety and trust in the industry. With companies like Hims & Hers at stake, the FDA's choice could also impact competition and innovation within the telehealth and longevity sectors.